Hosted on MSN3mon
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
The QWINT-1 study compared efsitora to daily injections of Sanofi’s SNY Lantus (insulin glargine) for 52 weeks in T2D patients using basal insulin for the first time. The QWINT-3 study compared ...
pharmaphorum5d
FDA rejects Novo Nordisk’s weekly basal insulin
Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...
Medscape12mon
Self-Mixed/Split Insulin Regimen
The section on insulin treatment discusses only three regimens: basal insulin alone when patients fail a combination of other agents, a basal/bolus regimen when patients fail basal insulin ...
pharmaphorum7d
Novo Nordisk once-weekly insulin clears first phase 3 test
Novo Nordisk said that if approved for use, insulin icodec would reduce the number of basal insulin injections needed per year for type 2 diabetics from 365 to 52, a significant reduction in ...
Knowridge14d
Common diabetes drugs are linked to higher heart disease risks
Two widely prescribed drugs for type 2 diabetes—sulfonylureas and basal insulin—may increase the risk of severe ...
Medscape2d
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute Equally to its Glucose-lowering Action
On days 2–5, pancreatic endocrine clamps were performed using somatostatin infusions of somatostatin and/or selective replacement of insulin and glucagon; day 2, GLP-1 plus basal insulin and ...
Nature1y
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Acrp30 is a circulating protein synthesized in adipose tissue. A single injection in mice of purified recombinant Acrp30 leads to a 2–3-fold elevation in circulating Acrp30 levels, which ...